BioLife Q2 Revenue Jumps 21% to $28.5M, Operating Income Swings to Profit
BLFS sits 90% above its 52-week low of $17.86.
Summary
BioLife Solutions delivered a strong Q2 with revenue up 21% YoY to $28.5 million, driven by its dominant biopreservation media franchise. GAAP operating income swung to a $1.7 million profit from a $16.1 million loss a year ago, while adjusted EBITDA hit $7.4 million — a 26% margin. The company's media is now embedded in 18 commercial cell and gene therapies and holds over 70% market share in U.S. clinical trials. This performance reinforces the rationale behind Repligen's $1.5 billion acquisition announced in July, which is expected to close in Q4 2026. The results show accelerating profitability and market penetration ahead of the merger.
At the time of this announcement, BLFS was trading at $33.93 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.7B. The 52-week trading range was $17.86 to $34.34. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: PR Newswire.